Join us at the 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology that will bring together international leading scientists and health care professionals who are actively working in Therapeutic Drug Monitoring and Clinical Toxicology.
Stop by and visit Waters to find out more about Waters latest technologies and innovations that enable superior performance in your lab.
Leveraging LC-MS in Therapeutic Drug Monitoring Development
Date & Time: Monday, September 25th, 9:40 am - 10:30 am (50 minutes)
Location: Room Swan, Kyoto International Conference Center
Expanding the Role of LC-MS/MS in Therapeutic Drug Monitoring (TDM)
Presented by Professor Yusuke Tanigawara, Keio University School of Medicine, Japan
Modern TDM has grown to cover a diverse selection of drugs ranging from small molecules to biologics. In this workshop, we will discuss the utility and benefit of LC-MS/MS in the application of TDM.
TDM by LC/MS- Single Analyte, Multiplexing and Novel Drugs
Presented by Gareth Hammond, Technical Manager, Clinical Scientist Operations, Waters Corporation, United Kingdom
This talk will take you through the principles, history and future of TDM using LC-MS/MS technology. Starting at the beginning with the development of the first single analyte immunosuppressant assay for tacrolimus (FK506). The specificity and selectivity of LC-MS/MS can simplify the development of multi-analyte (multiplex) panels, such as anti-depressants, antiepileptics and antifungals. The presentation will conclude with a look to the future and new TDM applications for anti-cancer drugs and the challenges to be addressed and overcome when analysing monoclonal antibodies.
|Please register from the English link if you are not a Japanese||日本国籍の方は日本語でのご登録をお願いします|
* To attend the Waters Workshop, you also need to register for IATDMCT 2017.
Date & Time: September 25th to 27th 10:00 am - 4:00 pm (Details are coming soon in the middle of July)
Location: Booth #9, Annex Hall, Kyoto International Conference Center
Please refer to this page below for all the Abstracts
LC-MS/MS Analysis of 5-Fluorouracil in Plasma for Clinical Research
Stephen Balloch, Lisa Calton and Gareth Hammond
5-Fluorouracil (5-FU) is an anti-cancer agent used predominantly in the study of several solid tumor cancers, including colorectal, pancreatic, breast, esophageal and head and neck tumors in clinical research. There is a high degree of inter-individual variability for 5-FU metabolism. An accurate, analytically sensitive and specific method may play a role in researching the pharmacokinetic and pharmacodynamic effects of 5-FU administration.
UPLC-MS/MS Analysis of Plasma Busulfan for Clinical Research
Stephen Balloch, Lisa Calton and Gareth Hammond
Busulfan is a bifunctional alkylating agent whose bioavailability varies greatly between individuals due to factors such as age, underlying diseases and drug-drug interactions. An accurate, sensitive and specific analytical method may play a role in assessing the pharmacokinetic and pharmacodynamic effects of busulfan administration in clinical research.
Quantitative Analysis of THC and Metabolites from Multiple Matrices Using UPLC-MS/MS for Forensic Toxicology Applications
Donald Mason, Jonathan Danaceau, Erin Chambers and Kim Haynes
Cannabis continues to be a highly abused recreational drug. The increasing number of states legalizing it for medical use, combined with the trend towards legalization for recreational purposes, means than analytical methods for the quantification of Δ-9-tetrahydrocannabinol (THC) and its metabolites continue to be necessary. In addition to urine and whole blood, there is a growing need for plasma- and oral fluid-specific analytical techniques. In addition to the unique analytical challenges posed by THC and its metabolites, the individual properties of these 4 matrices also need to be addressed during method development. This work details the optimization of methods for THC, 11-hydroxy Δ-9-THC (THC-OH) and 11-nor-9-Carboxy-Δ-9-THC (THC-COOH) in plasma, oral fluid (OF), whole blood, and urine. Further, the extraction and analysis these compounds from all 4 matrices using a novel reversed-phase sorbent, followed by direct analysis by UPLC-MS/MS is described. Matrix specific adjustments in SPE protocols and chromatographic methods were employed to optimize each analysis.
Evaluation of Tof-MRM for the Analysis of Illicit Drug Substances
Michelle Amari Finneran
Drug screening plays an important role in the success of European drug treatment programs and is used to confirm compliance and to monitor other illicit drug substances. Commonly, toxicology laboratory testing includes immunoassay screening and confirmatory using LC-MS/MS techniques. Some service providers have replaced this multiple step approach with a single LC-MS/MS procedure targeted for a selection of key analytes1. While both of these strategies represent effective procedures for a limited panel of analytes, the approach does not provide information for a broad range of drug substances. The aim of this study was to evaluate performance of time-of-flight-multiple reaction monitoring (Tof-MRM) and its potential to meet the requirements of the existing service while providing additional capabilities of broad comprehensive screening using the same instrumentation.